| 000 | 00909 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250513074637.0 | ||
| 264 | 0 | _c19930415 | |
| 008 | 199304s 0 0 eng d | ||
| 022 | _a0002-9343 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSörgel, F | |
| 245 | 0 | 0 |
_aPharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. _h[electronic resource] |
| 260 |
_bThe American journal of medicine _cMar 1993 |
||
| 300 |
_a56S-69S p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _a4-Quinolones |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney _xmetabolism |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 | _aTopoisomerase II Inhibitors |
| 700 | 1 | _aKinzig, M | |
| 773 | 0 |
_tThe American journal of medicine _gvol. 94 _gno. 3A _gp. 56S-69S |
|
| 999 |
_c8383194 _d8383194 |
||